Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors

NCT07479667 is registered in ClinicalTrials.gov with Shanghai Cell Therapy Group Co.,Ltd as lead sponsor.

NCT NCT07479667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07479667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors
Lead sponsor
Shanghai Cell Therapy Group Co.,Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
February 5, 2026
Completion date
June 30, 2029
Enrollment
8 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant therapy, solid cancers